Sensei Biotherapeutics, Inc.
SNSE
$0.3857
-$0.0192-4.74%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -43.08% | -18.70% | -40.61% | -34.30% | -34.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.61% | 1.11% | -23.48% | -20.69% | -36.07% |
| Operating Income | 20.61% | -1.11% | 23.48% | 20.69% | 36.07% |
| Income Before Tax | -4.80% | -1.81% | 23.91% | 21.47% | 39.39% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.80% | -1.81% | 23.91% | 21.47% | 39.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.80% | -1.81% | 23.91% | 21.47% | 39.39% |
| EBIT | 20.61% | -1.11% | 23.48% | 20.69% | 36.07% |
| EBITDA | 21.48% | -1.16% | 24.24% | 21.14% | 36.89% |
| EPS Basic | -4.01% | -3.30% | 7.54% | 3.22% | 25.41% |
| Normalized Basic EPS | 17.26% | -3.38% | 5.63% | 4.21% | 20.55% |
| EPS Diluted | -4.01% | -3.30% | 7.54% | 3.22% | 25.41% |
| Normalized Diluted EPS | 17.26% | -3.38% | 5.63% | 4.21% | 20.55% |
| Average Basic Shares Outstanding | 0.74% | -1.43% | -17.71% | -18.85% | -18.74% |
| Average Diluted Shares Outstanding | 0.74% | -1.43% | -17.71% | -18.85% | -18.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |